Skip to main content
. 2016 Jul 15;5(7):e1196299. doi: 10.1080/2162402X.2016.1196299

Figure 3.

Figure 3.

Macrophage-assisted ECM degradation and invasion by cancer cells is mediated by MIP-1β. (A and B) Representative images showing the effect of anti-human MIP-1β blockade by MIP-1β-neutralizing antibody (MIP-1β NA) or addition of MIP-1β-purified cytokine (MIP-1β) with respect to matrix protrusive activity, and invasion in MDA-MB-231 and MCF-7. IgG serve as isotype antibody control for MIP-1β-neutralizing antibody (MIP-1β NA). Cancer cells (MDA-MB-231 and MCF-7) treated with MIP-1β NA showed decreased activity in matrix protrusive activity and diminished invasion compared to cells that were not treated with MIP-1β NA. Cancer cells treated with MIP-1β-purified cytokine (MIP-1β) showed an increase in matrix protrusive activity and invasion compare to cells that did not treated with MIP-1β. Bars represent mean invadopodia count/cell from 10 fields per experiment and mean invasive cell count ±SE (*p < 0.05.). All the experiments were done in triplicates and repeated at least thrice. Abbreviations—C: Respective cancer Cells; C+M: Respective cancer cells co-cultured withMacrophages; C+M(IgG): Respective cancer cells co-cultured with macrophages treated with isotype antibody control IgG; C+M+MIP-1β NA: Respective cancer cells co-cultured with macrophages treated with MIP-1β-neutralizing antibody; MIP-1β: Respective cancer cells treated with MIP-1β-purified cytokine.